Feasibility of CXCR4-directed radioligand therapy in advanced diffuse large B-cell lymphoma

Lapa C, Haenscheid H, Kircher M, Schirbel A, Wunderlich G, Werner RA, Samnick S, Kotzerke J, Einsele H, Buck AK, Wester HJ, Grigoleit GU (2019)

Publication Type: Journal article

Publication year: 2019

Journal

Journal of Nuclear Medicine Society of Nuclear Medicine

Book Volume: 60

Pages Range: 60-64

Journal Issue: 1

DOI: 10.2967/jnumed.118.210997

Abstract

We have recently reported on our experience with C-X-C-motif chemokine receptor 4 (CXCR4)-directed radioligand therapy (RLT) in multiple myeloma and acute leukemia. Methods: Six patients with heavily pretreated relapsed diffuse large B-cell lymphoma (3 men, 3 women; aged, 54 ± 8 y) underwent CXCR4-directed RLT in combination with conditioning chemotherapy and allogeneic stem cell transplantation. In 2 patients, radioimmunotherapy targeting CD20 or CD66 was added to enhance antilymphoma activity. Endpoints were incidence and severity of adverse events, progression-free survival, and overall survival. Results: RLT and additional radioimmunotherapy were well tolerated, without any acute adverse events or changes in vital signs. Successful engraftment was recorded after a median of 11 d (range, 9-13 d). Of the 4 patients who were available for follow-up (one patient died of CNS aspergillosis 29 d after RLT and another of sepsis in aplasia 34 d after RLT), CXCR4-directed RLT resulted in a partial response in two (both treated with additional radioimmunotherapy) and a mixed response in the remaining two. The response duration was rather short-lived, with a median progression-free survival of 62 d (range, 29-110 d) and a median overall survival of 76 d (range, 29-334 d). Conclusion: CXCR4-directed RLT (in combination with additional radioimmunotherapy) is feasible as a conditioning regimen before allogeneic stem cell transplantation in diffuse large B-cell lymphoma.

Involved external institutions

Universitätsklinikum Würzburg DE Germany (DE) Universitätsklinikum Carl Gustav Carus Dresden DE Germany (DE) Technische Universität München (TUM) DE Germany (DE)

How to cite

APA:

Lapa, C., Haenscheid, H., Kircher, M., Schirbel, A., Wunderlich, G., Werner, R.A.,... Grigoleit, G.U. (2019). Feasibility of CXCR4-directed radioligand therapy in advanced diffuse large B-cell lymphoma. Journal of Nuclear Medicine, 60(1), 60-64. https://doi.org/10.2967/jnumed.118.210997

MLA:

Lapa, Constantin, et al. "Feasibility of CXCR4-directed radioligand therapy in advanced diffuse large B-cell lymphoma." Journal of Nuclear Medicine 60.1 (2019): 60-64.

BibTeX: Download